| Literature DB >> 30405431 |
M F Galvis-Ramírez1, J C Quintana-Castillo2, J C Bueno-Sanchez1.
Abstract
The polysaccharide heparan sulfate is ubiquitously expressed as a proteoglycan in extracellular matrices and on cell surfaces. In the glomerular filtration barrier, the action of the heparan sulfate is directly related to the function of glomerular filtration, mostly attributed to the sulfated domains that occur along the polysaccharide chain, as evidenced by fact that release of fragments of heparan sulfate by heparanase significantly increases the permeability of albumin passage through the glomerular endothelium, event that originates proteinuria. This review aims to show the importance of the structural domains of heparan sulfate in the process of selective permeability and to demonstrate how these domains may be altered during the glomerular inflammation processes that occur in preeclampsia.Entities:
Keywords: glomerular endothelia dysfunction; heparan sulfate (HS); preeclampsia; renal damage; systemic inflammatory response
Year: 2018 PMID: 30405431 PMCID: PMC6206159 DOI: 10.3389/fphys.2018.01470
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Inflammation of the glomerular endothelium causes the loss of HS, thereby triggering proteinuria in women with PE: a proposed model. In normal conditions (left side), the GFB performs its function of filtration, which is characterized by selective permeability to albumin due to HS in the glomerular endothelial glycocalyx, through its three layers. When a glomerular endothelial inflammation is established (right side), as is the case of PE, the increase in pro-inflammatory cytokines promotes the heparanase-mediated endoglucosidic activity of HS, which leads to the loss of anionic sites and, consequently, proteinuria.
Involvement of HS and heparanase expression in proteinuric diseases.
| Disease/Animal Model | Species | Glomerular Heparanase Expression | HS Expression | Proteinuria | Reference |
|---|---|---|---|---|---|
| Diabetic nephropathy | Human | Increased | Reduced | (+) | |
| Systemic lupus erythematosus | Human/mouse | Increased | Reduced | (+) | |
| Membranous glomerulonephritis | Human/mouse | Increased | Reduced | (+) | |
| Dense deposit disease | Human/Rat | Increased | Reduced | (+) | |
| Ig A nephropathy | Human | Increased | Reduced | (+) | |
| Minimal change disease | Human | Not analyzed | Reduced | (+) |